Leah Lawrence

2 months ago | oncologynewscentral.com | Youssef Rddad |Rabiya Tuma |Leah Lawrence

On March 21, the U.S. Food and Drug Administration (FDA) sent a letter from its Office of Prescription Drug Promotion to Taiho Oncology, claiming that data posted on the company’s healthcare provider branded website contained “false or misleading” claims about the benefits of futibatinib (Lytgobi) tablets used to treat certain bile duct cancers.